Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have been given an average recommendation of “Moderate Buy” by the fourteen brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $44.10.

A number of equities research analysts recently issued reports on OLMA shares. Wolfe Research assumed coverage on shares of Olema Pharmaceuticals in a report on Friday, March 27th. They issued a “peer perform” rating for the company. HC Wainwright reaffirmed a “buy” rating on shares of Olema Pharmaceuticals in a research report on Friday, May 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Tuesday, April 21st. Guggenheim decreased their price target on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Finally, The Goldman Sachs Group lowered their price objective on Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th.

Olema Pharmaceuticals Stock Performance

OLMA stock opened at $12.64 on Monday. The company has a quick ratio of 10.88, a current ratio of 10.88 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -6.26 and a beta of 2.00. Olema Pharmaceuticals has a 12 month low of $4.37 and a 12 month high of $36.26. The firm has a 50 day moving average of $12.43 and a two-hundred day moving average of $18.65.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.52). As a group, equities analysts anticipate that Olema Pharmaceuticals will post -2.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Olema Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC raised its position in shares of Olema Pharmaceuticals by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after purchasing an additional 477 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Olema Pharmaceuticals by 8.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,018 shares of the company’s stock valued at $325,000 after buying an additional 987 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Olema Pharmaceuticals by 44.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after buying an additional 1,169 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in Olema Pharmaceuticals by 9,476.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after buying an additional 1,232 shares during the last quarter. Finally, ProShare Advisors LLC raised its holdings in Olema Pharmaceuticals by 13.8% in the 4th quarter. ProShare Advisors LLC now owns 14,367 shares of the company’s stock worth $359,000 after acquiring an additional 1,740 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.